VIAL

Longevity & Healthspan Providers

17 verified Longevity providers in Vial’s directory.

What is Longevity?

The longevity medicine space has attracted significant buzz, with a large amount of capital, celebrity endorsement, and genuine scientific interest, often in that order. Clinics offering NAD infusions, peptide protocols, advanced diagnostics, and healthspan programs have grown faster than any meaningful quality standard has emerged to evaluate them. The gap between the best and worst providers is enormous. Vial maps the longevity provider landscape against federal compliance records and accreditation status to surface what marketing copy doesn't.

Top Longevity providers in Vial’s directory

Ranked by Trust Score. Showing 10 of 17. See all Longevity providers →

How Vial evaluates Longevity providers

Vial verifies longevity providers across six dimensions: regulatory standing, clinical transparency, pharmacy and fulfillment, commercial transparency, operating history, and industry standing. For longevity specifically, we weight clinical depth (lab panel breadth, physician credentialing, named protocols) over marketing breadth — the longevity space concentrates marketing claims and Vial's job is to separate the verifiable from the aspirational.

Read the full methodology →

Longevity compounds

Compounds commonly used in Longevity protocols. See all compounds →

MetabolicClinical Trials
NAD+
A coenzyme present in all living cells, nicotinamide adenine dinucleotide (NAD+) functions as a critical electron carrier in cellular metabolism and serves as a substrate for enzymes involved in DNA repair, cellular signaling, and epigenetic regulation. Cellular NAD+ levels decline with age, which has been associated with metabolic dysfunction and age-related pathologies. Research focuses on NAD+ precursor supplementation (such as nicotinamide riboside and nicotinamide mononucleotide) to investigate potential therapeutic applications in metabolic disorders, neurodegeneration, and aging-related conditions.
Legal Compounded→
PeptideClinical Trials
Sermorelin
A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.
Legal Compounded→
PeptideClinical Trials
CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.
Legal Compounded→
PeptideClinical Trials
Ipamorelin
A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.
Legal Compounded→
MetabolicPreclinical
MOTS-c
A mitochondrial-derived peptide encoded by the 12S rRNA gene, MOTS-c functions as a signaling molecule that regulates metabolic homeostasis by activating AMPK and influencing glucose uptake, insulin sensitivity, and fatty acid oxidation. This peptide has demonstrated effects on cellular metabolism and exercise mimetic properties in preclinical studies. Current research focuses on its potential applications in metabolic dysfunction, age-related decline, and insulin resistance.
Grey Area→
RecoveryPreclinical
BPC-157
A synthetic 15-amino-acid peptide derived from human gastric juice proteins, BPC-157 (Body Protection Compound-157) demonstrates cytoprotective and regenerative properties in preclinical studies. Research in animal models suggests it may accelerate healing of tendons, ligaments, muscle, and gastrointestinal tissue through mechanisms involving angiogenesis, growth factor modulation, and nitric oxide pathway regulation. While extensively studied in rodent injury models, human clinical trial data remains limited, and the compound is not currently approved for therapeutic use by major regulatory agencies.
Grey Area→
MetabolicClinical Trials
Metformin
Metformin is the world's most prescribed diabetes drug and a leading candidate for the first FDA-approved longevity drug via the TAME (Targeting Aging with Metformin) trial. Epidemiological data consistently shows metformin users have lower rates of cancer, cardiovascular disease, and all-cause mortality compared to matched diabetic controls. It is widely used off-label by longevity-focused physicians. Side effects are minimal at low doses.
FDA Approved→
MetabolicClinical Trials
Rapamycin
Rapamycin (sirolimus) is an FDA-approved immunosuppressant that is the most robust longevity-extending drug identified in animal models, extending lifespan in mice by 9–14% even when started late in life. It works by inhibiting mTORC1, a central nutrient-sensing pathway. Low-dose, intermittent protocols are being studied and self-administered by longevity researchers for healthspan extension. It carries meaningful immunosuppression risks requiring physician oversight.
FDA Approved→

Frequently Asked Questions

Related pillars

TRTPeptide TherapyWeight LossWomen's Health